{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:58:48Z","timestamp":1784667528739,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the impact of different treatment strategies and risk factors on the prognosis of patients with extranodal NK\/T-cell lymphoma, nasal type (ENKTL) in a single medical center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>The clinical features of 266 patients with ENKTL were retrospectively analyzed, among whom those in stages I and II received sandwich therapy, while those in stages III and IV underwent chemotherapy plus autologous hematopoietic stem cell transplantation. The Kaplan\u2013Meier curves, univariate and multivariate Cox regression analyses were employed for survival and prognosis analysis. Statistical significance was set at P&amp;lt;0.05.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Following treatment, the post-intervention outcomes demonstrated a complete remission (CR) rate of 71.05% and a partial remission (PR) rate of 3.76%. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 70.4% and 70.9%, respectively. In addition, the PFS for patients in stage I\/II was 79.8%, with an OS of 81.1%, whereas for those in stage III\/IV, the PFS was 41.7% and the OS was 40.9%. Notably, the achievement of CR immediately after treatment was an independent prognostic factor (P&amp;lt;0.001). Patients in stage I\/II depicted a favorable 5-year OS rate, while those in stage III\/IV manifested a less favorable prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Stages of the disease and whether CR was achieved following treatment are important factors determining the survival and prognosis of patients with ENKTL. Further researches focusing on disease onset and mechanisms of drug resistance will contribute to better management of ENKTL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1388564","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T04:56:13Z","timestamp":1712120173000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of the treatment and prognosis of 266 cases of extranodal natural killer\/T-cell lymphoma, nasal type in a single medical center"],"prefix":"10.3389","volume":"14","author":[{"given":"Lei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-185256","article-title":"Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project","volume":"113","author":"Au","year":"2009","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0355-9","article-title":"Extranodal NK\/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases","volume":"11","author":"Haverkos","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11899-018-0430-5","article-title":"NK\/T cell lymphoma: updates in therapy","volume":"13","author":"Suzuki","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-018-0687-0","article-title":"Treatment of localized extranodal NK\/T cell lymphoma, nasal type: a systematic review","volume":"11","author":"Kim","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01313-2","article-title":"NK-\/T-cell lymphomas","volume":"35","author":"Wang","year":"2021","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hon.65_2629","article-title":"Treatment benefit associating with non-anthracycline chemotherapy in extranodal NK\/T-cell lymphoma, nasal type","volume":"37","author":"Qi","year":"2019","journal-title":"Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for Malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00417","article-title":"Overview of EBV-associated T\/NK-cell lymphoproliferative diseases","volume":"6","author":"Kimura","year":"2019","journal-title":"Front Pediatr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B12","article-title":"Distribution pattern of lymphoma subtypes in China: a nationwide multicenter study of 10002 cases","volume":"11","author":"Gan-di","year":"2012","journal-title":"J Diagn Concepts Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01319.x","article-title":"Extranodal NK \/ T-cell lymphoma, nasal type: new staging system and treatment strategies","volume":"100","author":"Kim","year":"2009","journal-title":"Cancer Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/10245330400026162","article-title":"NK-cell neoplasms in Japan","volume":"10","author":"Oshimi","year":"2005","journal-title":"Hematology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.06.005","article-title":"NK\/T-cell lymphomas","volume":"32","author":"Tse","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.02.011","article-title":"Modern radiation therapy for extranodal nasal-type NK\/T-cell lymphoma: risk-adapted therapy, target volume, and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"110","author":"Qi","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.radonc.2018.04.026","article-title":"Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK\/T-cell lymphoma: a multicenter study from the China Lymphoma Collaborative Group (CLCG)","volume":"129","author":"Deng","year":"2018","journal-title":"Radiother Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells","volume":"76","author":"Yamaguchi","year":"1995","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001852","article-title":"First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK\/T-cell lymphoma: a retrospective analysis from the CLCG","volume":"4","author":"Qi","year":"2020","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hon.2588","article-title":"What we should know about natural killer\/T-cell lymphomas","volume":"37","author":"Xiong","year":"2019","journal-title":"Hematol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx684","article-title":"Sequential chemotherapy\/radiotherapy was comparable with concurrent chemoradiotherapy for stage I\/II NK\/T-cell lymphoma","volume":"29","author":"Kwong","year":"2018","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s12032-013-0720-7","article-title":"Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer(NK)\/T cell lymphoma, nasal type","volume":"30","author":"Yang","year":"2013","journal-title":"Med Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1182\/blood-2019-128435","article-title":"Toxicity of a modified Pegasparaginase-based SMILE regimen is comparable to L-asparaginase-based SMILE in a non-Asian population","volume":"134","author":"Caddell","year":"2019","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1811864","article-title":"(mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population","volume":"61","author":"Ghione","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.20892\/j.issn.2095-3941.2020.0160","article-title":"Outcomes of patients treated with SVILE vs. P-Gemox for extranodal natural killer\/T-cell lymphoma, nasal type: a prospective, randomized controlled study","volume":"17","author":"Wei","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130984","article-title":"A TNM staging system for nasal NK\/T-cell lymphoma","volume":"10","author":"Yan","year":"2015","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0791-3","article-title":"Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making","volume":"35","author":"Chen","year":"2021","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1388564\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T04:56:15Z","timestamp":1712120175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1388564\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":30,"alternative-id":["10.3389\/fonc.2024.1388564"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1388564","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"article-number":"1388564"}}